However, this was an observational study, so it does not establish causality, and GLP-1 agents should not yet be considered primary treatments for depression or anxiety, he told Healthline
Production follows GMP and ISO standards, and each batch is traceable and compliant with IP/USP pharmacopoeial requirements, ensuring quality and regulatory satisfaction for your business
Medicare currently covers GLP-1s for diabetes and certain related cardiovascular conditions, but coverage for weight loss alone remains limited
Health Canada has not approved either peptide for therapeutic use, which is typical for compounds still in clinical development
Allergic Reactions: Though rare, some people may develop a rash or hives
Obesity Research , 6(2), 97106.